BRAF and melanoma: At 48 h after treatment, we found that ECCA significantly inhibited the growth of all melanoma cell lines tested at 1 μM no matter whether they harbored a wild-type or a mutated BRAF gene, and the inhibitory effect occurred in a dose-dependent manner (Fig. 1A), although UACC62 cells were more sensitive to ECCA.